A recently published letter to the editor in Annals of Oncology, authored by Dr. Vincenzo Di Noia from the Regina Elena National Cancer Institute in Rome, Italy, "described the serological response to the third dose of the BNT162b2 mENA COVID-19 vaccine in a large cohort of patients with cancer." 407 patients received a third dose of BN1162b3 between September - November 2021. 366 (89.9%) of patients were on active anticancer treatment 28 days before BNT162b2 was administered. Median age of patients was 67, with breast (28.5%) and lung (19.9%) identified as the most common cancer types. 402 (98.8%) of patients studied "had a positive serological status after the third vaccine dose."
To read more about this study, click here.
Study mentioned: Di Noia V, Pimpinelli F, Renna D, et al. Potentiation of humoral response to BNT162b2 vaccine after the third dose in patients with solid cancer. Annals of Oncology; Published online 21 February 2022. doi: https://doi.org/10.1016/j.annonc.2022.02.006
No comments:
Post a Comment